Akso Health Group (NASDAQ: AHG) ("Akso Health" or the "Company") announced the launch of the an exploratory patient support program and a strategic cooperation with Nanning Duoling Research Institute. Adopting an integrated model of "Traditional Chinese Medicine (TCM) practice + modern medical technology", certain medical resources will be coordinated and integrated to provide free in-hospital treatment plans for up to 10,000 eligible patients within participating medical institutions. The patient support program directly addresses the urgent needs of cancer patients and reconstructs the standards of medical accessibility through "global resource integration + zero-cost access".

Akso Health plans to open its global medical network, connecting the radiation oncology centers under its planning and construction withtargeted drugs andremote consultation teams. Pursuant to a strategic cooperation framework agreement, Nanning Duoling will provide its exclusive cancer diagnosis and treatment technologies, reagent and consumable supply system, professional laboratory testing capabilities, and an exclusive team composed of experts in the field of cancer diagnosis and treatment. 

The two parties will work together to build a closed-loop model of "global resource connection + local technology landing + full-cycle patient service", and the core breakthrough of this model is "zero-cost full-chain coverage", which directly addresses the core pain points of high medical costs, difficulty in accessing medical care, and uneven treatment effects faced by more than 20 million new cancer patients worldwide and 4.06 million new annual cases in China.

This program is an important initiative for the Company to continuously explore how to improve the actual accessibility of specific medical support resources within the compliant medical system. It aims to explore a potential framework for coordinating and integrating third-party medical resources through licensed and compliant medical institutions to help patients obtain specific medical services. Any services that may be provided under the program will be fully offered by independent medical institutions and licensed medical professionals, rather than directly by the Company. Specific arrangements, if any, must meet conditions such as patient eligibility, institutional qualifications, applicable regulatory requirements, and funding accessibility.

The Company believes that the launch of this exploratory global patient support initiative may allow for further assessment of scalability and feasibility, subject to ongoing review.

Akso Health emphasized that the long-term value of healthcare innovation lies not only in research and development, but also in the ability to responsibly evaluate implementation models within real-world medical systems. Through the integration of institutional experience, research collaboration, and system-level coordination, the Company continues to explore ways to support sustainable and compliant healthcare accessibility.

Yilin (Linda) Wang, Chief Executive Officer of Akso Health Group, stated,
"We believe it is important to responsibly explore ways to support broader access to healthcare resources, while fully respecting regulatory boundaries and the essential role of licensed medical professionals. This initiative represents an early-stage effort, and we intend to proceed cautiously and deliberately."

The initiative is designed to assess potential approaches to enhancing healthcare accessibility through structured coordination and support mechanisms, while maintaining a clear separation between the Company's corporate activities and the delivery of regulated medical services. Participation, if available, would be offered on a limited and phased basis and does not involve any commercial promotion of medical products or therapies.